CN107198767A - 一种用于预防三高的红曲苦瓜复合肽片 - Google Patents
一种用于预防三高的红曲苦瓜复合肽片 Download PDFInfo
- Publication number
- CN107198767A CN107198767A CN201710358964.7A CN201710358964A CN107198767A CN 107198767 A CN107198767 A CN 107198767A CN 201710358964 A CN201710358964 A CN 201710358964A CN 107198767 A CN107198767 A CN 107198767A
- Authority
- CN
- China
- Prior art keywords
- parts
- lys
- gly
- red yeast
- yeast rice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 229940026314 red yeast rice Drugs 0.000 title claims abstract description 35
- 244000302512 Momordica charantia Species 0.000 title claims abstract description 18
- 235000009811 Momordica charantia Nutrition 0.000 title claims abstract description 18
- 235000009812 Momordica cochinchinensis Nutrition 0.000 title claims abstract description 18
- 235000018365 Momordica dioica Nutrition 0.000 title claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 15
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 58
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims abstract description 58
- 239000000843 powder Substances 0.000 claims abstract description 43
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010088751 Albumins Proteins 0.000 claims abstract description 21
- 102000009027 Albumins Human genes 0.000 claims abstract description 21
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 20
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 20
- 229920001202 Inulin Polymers 0.000 claims abstract description 20
- 235000021307 Triticum Nutrition 0.000 claims abstract description 20
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 20
- 229940029339 inulin Drugs 0.000 claims abstract description 20
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 19
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 19
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 19
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 15
- 229940035035 polydextrose Drugs 0.000 claims abstract description 15
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 15
- 239000001259 polydextrose Substances 0.000 claims abstract description 15
- -1 oligoisomaltose Chemical compound 0.000 claims abstract description 3
- 244000194101 Ginkgo biloba Species 0.000 claims abstract 3
- 241000209140 Triticum Species 0.000 claims description 19
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 244000018633 Prunus armeniaca Species 0.000 claims 1
- 235000009827 Prunus armeniaca Nutrition 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 2
- 244000098338 Triticum aestivum Species 0.000 abstract 1
- 235000019629 palatability Nutrition 0.000 abstract 1
- 241000218628 Ginkgo Species 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000011812 mixed powder Substances 0.000 description 12
- 239000011122 softwood Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- 235000014347 soups Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000020985 whole grains Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical group OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种用于预防三高的红曲苦瓜复合肽片，包括以下组份：小麦低聚肽粉、大豆肽粉、胶原蛋白肽粉、白蛋白肽粉、聚葡萄糖、低聚异麦芽糖、菊粉、红曲、苦瓜提取物、银杏粉、茶多酚。本产品不仅适口性好，而且对三高患者的症状改善有较为显著的效果。
Description
技术领域
本发明属于一种保健医药领域，具体属于一种用于预防三高的红曲苦瓜复合肽片。
背景技术
“三高症”是指高血压、高血糖(糖尿病)和高脂血症。它们是现代社会所派生出来的“富贵病”，可能单独存在，也可能相互关联。如：糖尿病人很容易同时患上高血压或高血脂症，而高血脂又是动脉硬化形成和发展的主要因素，动脉硬化患者血管弹性差加剧血压升高。所以，出现这三种疾患中的任何一种，后期都易形成了“三高症”。
(一)高血压
高血压病是当代最常见的流行病之一，早期高血压病人可表现头痛、头晕、耳鸣、心悸、眼花、注意力不集中、记忆力减退、手脚麻木、疲乏无力、易烦躁等症状，这些症状多为高级神经功能失调所致，其轻重与血压增高程度可不一致。
后期血压常持续在较高水平，并伴有脑、心、肾等器官受损的表现。这些器官受损可以是高血压直接损害造成的，也可以是间接地通过加速动脉粥样硬化性疾病产生而造成的。这些器官受损的早期可无症状，最后导致功能障碍，甚至发生衰竭。
(二)高血糖
最常见的高血糖症是糖尿病。糖尿病是一种慢性、终生性疾病，是一种严重危害人体健康的常见病，由于胰岛素相对或绝对不足，使体内碳水化合物、脂肪、蛋白质等营养素代谢异常。此病可引起多种并发症，严重时可以引起全身性疾病，使人致残、致盲，甚至致死。糖尿病的症状为“三多一少”，即多尿、多饮、多食及体重下降。高血糖病人要注意控制饮食，低糖低盐，加强锻炼，如果过段时间再查血糖还是高，也应考虑用降血糖的药。
(三)高血脂
高血脂是指血中胆固醇或甘油三酯过高或高密度脂蛋白胆固醇过低，现代医学称之为血脂异常。如果血脂过多，容易造成“血稠”，在血管壁上沉积，逐渐形成动脉粥样硬化，逐渐堵塞血管，使血流变慢，严重时血流中断。
这种情况如果发生在心脏，就会引起冠心病；发生在脑部会出现脑中风；如果堵塞眼底血管，将导致视力下降、失明；如果发生在肾脏，就会引起肾动脉硬化，肾功能衰竭；发生在下肢，会出现肢体坏死、溃烂等。此外，高血脂可引发高血压、诱发胆结石、胰腺炎，加重肝炎、老年痴呆等疾病。要降血脂可多食用维生素C片、银杏软胶囊、液体钙之类的物质。
临床对三高的预防，现在一般用西药降压降糖降脂药，这些药物一般副作用大，往往一旦服用便需终生服用，不能达到标本兼治的目的，而且有些药物还有停药反应，所以，如何利用中医基础理论，结合中药材的优势，发明一种疗效显著、副作用小的中药或保健品成为临床亟需解决的问题。
发明内容
技术问题：本发明针对三高人群的症状，提供一种用于预防三高的红曲苦瓜复合肽片。
技术方案：本发明提供一种用于预防三高的红曲苦瓜复合肽片，包括以下原料：小麦低聚肽粉、大豆肽粉、胶原蛋白肽粉、白蛋白肽粉、聚葡萄糖、低聚异麦芽糖、菊粉、红曲、苦瓜提取物、银杏粉、茶多酚。
作为一种优选，各原料重量配比如下：小麦低聚肽粉15-25份、大豆肽粉15-25份、胶原蛋白肽粉2-6份、白蛋白肽粉1-3份、聚葡萄糖5-9份、低聚异麦芽糖8-12份、菊粉2-5份、红曲3-12份、苦瓜提取物3-12份、银杏粉2-6份、茶多酚0.15-1.25份。
作为进一步优选：各原料重量配比如下：小麦低聚肽粉20份、大豆肽粉20份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份。
有益效果：本配方能够有效预防三高，同时减少服用的不适感，作用缓和，无副作用。
小麦低聚肽粉：可调节人的血糖，改善糖尿病症状，能阻碍血管紧张素酶的作用，具有降血压的效果，含高谷酰胺，能够有效调节神经，可作肠功能障碍时的特殊营养物质。
大豆肽粉：营养丰富、人体易吸收，还具有抗高血压、降低胆固醇、抗血栓形成，改善脂质代谢，促进肌红细胞复原，消除疲劳等调节功能。
胶原蛋白肽粉：可加快血管壁新陈代谢，增加血管壁弹性。
白蛋白肽粉：可维持血浆渗透压、增加血容量。
红曲米提取物：降低胆固醇效果好。
苦瓜提取物：号称植物胰岛素，具有良好的降血糖功效，无毒副作用。
具体实施方式
下面通过实验进一步阐述本发明的有益效果，通过实施例进一步阐述本发明。
本实验原料药品来源厂家及型号如下表：
| 药品名称 | 生产厂家 |
| 小麦低聚肽粉 | 山东天久生物技术有限公司 |
| 大豆肽粉 | 诺利如一(安阳)生物科技有限公司 |
| 胶原蛋白肽粉 | 山东天久生物技术有限公司 |
| 白蛋白肽粉 | 山东天久生物技术有限公司 |
| 聚葡萄糖 | 山东百龙创元生物科技有限公司 |
| 低聚异麦芽糖 | 山东百龙创元生物科技有限公司 |
| 菊粉 | 陕西森弗天然制品有限公司 |
| 苦瓜提取物 | 陕西森弗天然制品有限公司 |
| 银杏粉 | 陕西森弗天然制品有限公司 |
实施例1
预防三高的红曲苦瓜复合肽片，各原料重量配比如下：小麦低聚肽粉15份、大豆肽粉15份、胶原蛋白肽粉2份、白蛋白肽粉1份、聚葡萄糖5份、低聚异麦芽糖8份、菊粉2份、红曲3份、苦瓜提取物3份、银杏粉2份、茶多酚0.15份。
其制备过程，包括以下步骤：
称取小麦低聚肽粉15份、大豆肽粉15份、胶原蛋白肽粉2份、白蛋白肽粉1份、聚葡萄糖5份、低聚异麦芽糖8份、菊粉2份、红曲3份、苦瓜提取物3份、银杏粉2份、茶多酚0.15份，混合得总混合粉；在总混合粉中加入纯净水，得软材；将软材用40目筛制粒，得湿颗粒；将湿颗粒在60℃干燥至水分＜5％，40目筛整粒，得干颗粒；将干颗粒压片，得片剂，600mg/片。
实施例2
预防三高的红曲苦瓜复合肽片，各原料重量配比如下：小麦低聚肽粉20份、大豆肽粉20份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份。
其制备过程，包括以下步骤：
称取小麦低聚肽粉20份、大豆肽粉20份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份，混合得总混合粉；在总混合粉中加入纯净水，得软材；将软材用40目筛制粒，得湿颗粒；将湿颗粒在60℃干燥至水分＜5％，40目筛整粒，得干颗粒；将干颗粒压片，得片剂，600mg/片。
实施例3
预防三高的红曲苦瓜复合肽片，各原料重量配比如下：小麦低聚肽粉25份、大豆肽粉25份、胶原蛋白肽粉6份、白蛋白肽粉3份、聚葡萄糖9份、低聚异麦芽糖12份、菊粉5份、红曲12份、苦瓜提取物12份、银杏粉6份、茶多酚1.25份。
其制备过程，包括以下步骤：
称取小麦低聚肽粉25份、大豆肽粉25份、胶原蛋白肽粉6份、白蛋白肽粉3份、聚葡萄糖9份、低聚异麦芽糖12份、菊粉5份、红曲12份、苦瓜提取物12份、银杏粉6份、茶多酚1.25份，混合得总混合粉；在总混合粉中加入纯净水，得软材；将软材用40目筛制粒，得湿颗粒；将湿颗粒在60℃干燥至水分＜5％，40目筛整粒，得干颗粒；将干颗粒压片，得片剂，600mg/片。
对比例1
预防三高的红曲苦瓜复合肽片，各原料重量配比如下：小麦低聚肽粉40份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份。
其制备过程，包括以下步骤：
称取小麦低聚肽粉40份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份，混合得总混合粉；在总混合粉中加入纯净水，得软材；将软材用40目筛制粒，得湿颗粒；将湿颗粒在60℃干燥至水分＜5％，40目筛整粒，得干颗粒；将干颗粒压片，得片剂，600mg/片。
对比例2
预防三高的红曲苦瓜复合肽片，各原料重量配比如下：大豆肽粉40份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份。
其制备过程，包括以下步骤：
称取大豆肽粉40份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份，混合得总混合粉；在总混合粉中加入纯净水，得软材；将软材用40目筛制粒，得湿颗粒；将湿颗粒在60℃干燥至水分＜5％，40目筛整粒，得干颗粒；将干颗粒压片，得片剂，600mg/片。
对比例3
预防三高的红曲苦瓜复合肽片，各原料重量配比如下：小麦低聚肽粉25份、大豆肽粉25份、胶原蛋白肽粉6份、白蛋白肽粉3份、低聚异麦芽糖12份、菊粉5份、红曲12份、苦瓜提取物12份、银杏粉6份、茶多酚1.25份。
其制备过程，包括以下步骤：
称取小麦低聚肽粉25份、大豆肽粉25份、胶原蛋白肽粉6份、白蛋白肽粉3份、低聚异麦芽糖12份、菊粉5份、红曲12份、苦瓜提取物12份、银杏粉6份、茶多酚1.25份，混合得总混合粉；在总混合粉中加入纯净水，得软材；将软材用40目筛制粒，得湿颗粒；将湿颗粒在60℃干燥至水分＜5％，40目筛整粒，得干颗粒；将干颗粒压片，得片剂，600mg/片。
药效学实验
本产品可煎服、泡服、散剂、颗粒、片剂等剂型。
药物试验
一般资料：
取来诊高血压、高血糖、高血脂三高病例500例，年龄在25-75之间，平均年龄53.6岁。
诊断标准
高血脂：参照《中药新药临床研究指导原则》和2007年《中国成人血脂异常防治指南》标准进行评定。
高血压：临床诊断均符合世界卫生组织(WTO)规定的标准，即预防前基础血压大于等于160/95mmHg。
高血糖：参照1999年WTOT2DM诊断标准，中医诊断标准参照《中药新药临床研究指导原则(试行)》中消渴的中医辨证标准。
服用方法
服用本发明实施例1至3和对比例1至3的药物，每次10g，一日2次泡服，分两次服用，1个月为一个疗程，2个疗程后复诊，检查预防效果。
疗效结果
由上表可知：本配方的红曲苦瓜复合肽片在预防三高方面效果显著。
Claims (3)
1.一种用于预防三高的红曲苦瓜复合肽片，其特征在于：包括以下组份：小麦低聚肽粉、大豆肽粉、胶原蛋白肽粉、白蛋白肽粉、聚葡萄糖、低聚异麦芽糖、菊粉、红曲、苦瓜提取物、银杏粉、茶多酚。
2.根据权利要求1所述的一种用于预防三高的红曲苦瓜复合肽片，其特征在于：各组份重量份如下：小麦低聚肽粉15-25份、大豆肽粉15-25份、胶原蛋白肽粉2-6份、白蛋白肽粉1-3份、聚葡萄糖5-9份、低聚异麦芽糖8-12份、菊粉2-5份、红曲3-12份、苦瓜提取物3-12份、银杏粉2-6份、茶多酚0.15-1.25份。
3.根据权利要求1或者2所述的一种用于预防三高的红曲苦瓜复合肽片，其特征在于：各组份重量份如下：小麦低聚肽粉20份、大豆肽粉20份、胶原蛋白肽粉4份、白蛋白肽粉2份、聚葡萄糖7.5份、低聚异麦芽糖9.75份、菊粉3.75份、红曲7.5份、苦瓜提取物7.5份、银杏粉4.5份、茶多酚0.75份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710358964.7A CN107198767A (zh) | 2017-05-19 | 2017-05-19 | 一种用于预防三高的红曲苦瓜复合肽片 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710358964.7A CN107198767A (zh) | 2017-05-19 | 2017-05-19 | 一种用于预防三高的红曲苦瓜复合肽片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107198767A true CN107198767A (zh) | 2017-09-26 |
Family
ID=59906155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710358964.7A Pending CN107198767A (zh) | 2017-05-19 | 2017-05-19 | 一种用于预防三高的红曲苦瓜复合肽片 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107198767A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107668704A (zh) * | 2017-09-30 | 2018-02-09 | 太原华欣康中医门诊部 | 一种组合物 |
| CN107712914A (zh) * | 2017-11-20 | 2018-02-23 | 中食都庆（山东）生物技术有限公司 | 一种具有降脂功能的复方产品及其制备方法 |
| CN108617957A (zh) * | 2018-05-10 | 2018-10-09 | 丽睿客信息科技（北京）有限公司 | 具有降脂功效的营养食品 |
| CN110115757A (zh) * | 2019-06-18 | 2019-08-13 | 中食都庆（山东）生物技术有限公司 | 一种银杏叶提取物与豆肽复方降糖制剂及其制备方法 |
| CN110881666A (zh) * | 2019-12-12 | 2020-03-17 | 西咸新区优恩生物科技股份有限公司 | 一种航天员专用营养体质的小分子复合肽制剂 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507494A (zh) * | 2009-02-12 | 2009-08-19 | 刘志伟 | 高血脂高血压患者用的特殊膳食用食品 |
| CN102600227A (zh) * | 2012-03-05 | 2012-07-25 | 吴江谷力生物科技有限公司 | 复方功能性红曲胶囊 |
| CN103861086A (zh) * | 2014-03-07 | 2014-06-18 | 东营倍康生物科技有限公司 | 一种苦瓜肽***糖复合片的制作方法 |
| CN104397188A (zh) * | 2014-12-04 | 2015-03-11 | 保龄宝生物股份有限公司 | 一种含益生元的低热量固体奶茶及其制备方法 |
-
2017
- 2017-05-19 CN CN201710358964.7A patent/CN107198767A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507494A (zh) * | 2009-02-12 | 2009-08-19 | 刘志伟 | 高血脂高血压患者用的特殊膳食用食品 |
| CN102600227A (zh) * | 2012-03-05 | 2012-07-25 | 吴江谷力生物科技有限公司 | 复方功能性红曲胶囊 |
| CN103861086A (zh) * | 2014-03-07 | 2014-06-18 | 东营倍康生物科技有限公司 | 一种苦瓜肽***糖复合片的制作方法 |
| CN104397188A (zh) * | 2014-12-04 | 2015-03-11 | 保龄宝生物股份有限公司 | 一种含益生元的低热量固体奶茶及其制备方法 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107668704A (zh) * | 2017-09-30 | 2018-02-09 | 太原华欣康中医门诊部 | 一种组合物 |
| CN107712914A (zh) * | 2017-11-20 | 2018-02-23 | 中食都庆（山东）生物技术有限公司 | 一种具有降脂功能的复方产品及其制备方法 |
| CN108617957A (zh) * | 2018-05-10 | 2018-10-09 | 丽睿客信息科技（北京）有限公司 | 具有降脂功效的营养食品 |
| CN110115757A (zh) * | 2019-06-18 | 2019-08-13 | 中食都庆（山东）生物技术有限公司 | 一种银杏叶提取物与豆肽复方降糖制剂及其制备方法 |
| CN110881666A (zh) * | 2019-12-12 | 2020-03-17 | 西咸新区优恩生物科技股份有限公司 | 一种航天员专用营养体质的小分子复合肽制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107198767A (zh) | 一种用于预防三高的红曲苦瓜复合肽片 | |
| CN103099089B (zh) | 一种降糖、降压、通便减肥、抗疲劳、改善性功能保健品及其生产工艺 | |
| CN106983052A (zh) | 一种辅助降血糖的固体饮料及其制备方法 | |
| CN104366636A (zh) | 一种平卧菊三七复合制剂及制备方法及应用 | |
| CN102526479B (zh) | 一种增强免疫力、降血糖功能的保健药物 | |
| CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
| CN106038704A (zh) | 一种用于抑制食物消化吸收的组合物、制备方法及用途 | |
| WO2014131344A1 (zh) | 一种饮料 | |
| CN102178314A (zh) | 一种辅助降血压功能的苦荞保健饮料及其生产工艺 | |
| CN102907606B (zh) | 一种β-葡聚糖组合物及其应用 | |
| CN101366521B (zh) | 天然型功能食品 | |
| CN108391785A (zh) | 一种功能性代餐粉及其制作工艺与应用 | |
| CN108813350A (zh) | 一种降血糖、辅助治疗糖尿病的面条的配方及其制备工艺 | |
| CN103141776A (zh) | 一种营养组合物及其用途 | |
| CN106176953A (zh) | 一种包含青钱柳叶、罗汉果和桑叶的降血糖保健组合物 | |
| JP2019210269A (ja) | 糖尿疾患の治療用組成物 | |
| CN105707386A (zh) | 一种预防高血压的牛蒡复合压片糖果及其制备方法 | |
| CN102204650B (zh) | 一种低血糖指数保健主食及其制备方法与降血糖应用 | |
| CN103535625A (zh) | 一种调控血糖的食品及其制备方法 | |
| CN102652561A (zh) | 治疗微病症或辅助药物康复病体的植物蛋白食品及生产方法 | |
| CN109123414A (zh) | 一种胰岛素抵抗综合征人群的营养食品及其制备方法 | |
| CN109771578A (zh) | 防治糖尿病及并发症的组合物 | |
| CN108403818A (zh) | 一种辅助降血糖的组合物及其用途 | |
| CN109275906A (zh) | 一种多种植物复配减肥剂的制备方法 | |
| GB2507254A (en) | Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170926 |
|
| RJ01 | Rejection of invention patent application after publication |